ARTICLE | Targets & Mechanisms
Switching targets to avoid resistance to CAR Ts
Overcoming resistance to traditional CAR Ts with CARs against an alternative B cell target
September 25, 2019 10:26 PM UTC
City of Hope researchers have engineered CAR T cells directed against a new B cell target that could overcome resistance to or replace canonical CAR Ts.
The novel CAR T therapy against TNFRSF13c, which was showcased in a Science Translational Medicine paper published Wednesday, has been licensed to PeproMene Bio Inc. The Irvine, Calif.-based company will fund a Phase I trial in acute lymphoblastic leukemia (ALL) patients who have relapsed following anti-CD19 therapy. ...
BCIQ Company Profiles